Hosted on MSN2h
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.
The American Journal of Managed Care10h
FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
Hosted on MSN11h
What Is a Breast Cancer Rash? A Doctor Explains
A breast cancer rash can look like a harmless skin irritation—but there’s a notable difference. Cancer doctors explain why it ...
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Becker's Hospital Review16h
Breast cancer rates by state
The overall average breast cancer incidence rate in the U.S. was 131.8 per 100,000 and the overall average breast cancer mortality rate was 19.3 per 100,000. Among women in the U.S., breast cancer ...
FDA grants breakthrough designation to PreludeDx’s DCIS test
The US Food and Drug Administration (FDA) has granted breakthrough device designation to PreludeDx's DCISionRT test, a risk ...